Symbols / GHRS Stock $18.95 -8.23% GH Research PLC
GHRS (Stock) Chart
About
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
Stock Fundamentals
Scroll to Statements| Market Cap | 1.18B | Enterprise Value | 895.26M | Income | -48.26M | Sales | — | Book/sh | 4.51 | Cash/sh | 4.53 |
| Dividend Yield | — | Payout | 0.00% | Employees | 73 | IPO | — | P/E | — | Forward P/E | -10.32 |
| PEG | — | P/S | — | P/B | 4.20 | P/C | — | EV/EBITDA | -14.77 | EV/Sales | — |
| Quick Ratio | 33.65 | Current Ratio | 34.13 | Debt/Eq | 0.18 | LT Debt/Eq | — | EPS (ttm) | -0.79 | EPS next Y | -1.84 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-05-07 | ROA | -15.92% | ROE | -21.04% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 62.03M | Shs Float | 22.80M | Short Float | 10.91% |
| Short Ratio | 9.82 | Short Interest | — | 52W High | 24.66 | 52W Low | 8.75 | Beta | 1.00 | Avg Volume | 218.79K |
| Volume | 533.42K | Target Price | $39.25 | Recom | None | Prev Close | $20.65 | Price | $18.95 | Change | -8.23% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$39.25
Mean price target
2. Current target
$18.95
Latest analyst target
3. DCF / Fair value
$-8.86
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$18.95
Low
$25.00
High
$70.00
Mean
$39.25
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-06 | main | Citizens | Market Outperform → Market Outperform | $42 |
| 2026-03-06 | main | Needham | Buy → Buy | $32 |
| 2026-03-02 | main | HC Wainwright & Co. | Buy → Buy | $70 |
| 2026-01-23 | main | RBC Capital | Outperform → Outperform | $40 |
| 2026-01-06 | main | Canaccord Genuity | Buy → Buy | $39 |
| 2026-01-06 | main | Needham | Buy → Buy | $29 |
| 2026-01-05 | reit | Needham | Buy → Buy | $19 |
| 2025-11-10 | main | HC Wainwright & Co. | Buy → Buy | $35 |
| 2025-10-13 | init | Needham | — → Buy | $19 |
| 2025-06-24 | reit | JMP Securities | Market Outperform → Market Outperform | $39 |
| 2025-05-09 | main | Guggenheim | Buy → Buy | $29 |
| 2025-05-09 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-03-13 | init | Guggenheim | — → Buy | $32 |
| 2025-03-07 | init | RBC Capital | — → Outperform | $31 |
| 2025-02-27 | main | Stifel | Buy → Buy | $32 |
| 2025-02-13 | init | Cantor Fitzgerald | — → Overweight | $14 |
| 2025-01-27 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-01-13 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-01-10 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2024-11-20 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
- Is GH (GHRS) stock cyclical or defensive | Q4 2025: Profit Surprises - Attention Driven Stocks - Cổng thông tin điện tử tỉnh Lào Cai Wed, 22 Apr 2026 23
- White House mental illness order aligns with GH Research's 2026 Phase 3 plan - Stock Titan Mon, 20 Apr 2026 13
- Understanding Momentum Shifts in (GHRS) - Stock Traders Daily ue, 21 Apr 2026 09
- GH Research: WH Decision On Psychedelics To Treat Depression Makes Bull Case (NASDAQ:GHRS) - Seeking Alpha Mon, 20 Apr 2026 15
- Here's Why We're Not At All Concerned With GH Research's (NASDAQ:GHRS) Cash Burn Situation - Yahoo Finance Sat, 04 Apr 2026 07
- Why Is GHRS Stock Rising Today? - Stocktwits hu, 05 Mar 2026 08
- GH Research PLC to Provide Update on IND Application and Phase 3 Program for GH001 in Treatment-Resistant Depression | GHRS Stock News - Quiver Quantitative Fri, 02 Jan 2026 08
- Duncan Moore of GH Research (NASDAQ: GHRS) reports shares and vested options - Stock Titan Fri, 17 Apr 2026 22
- Cybin stands out as the most undervalued psychedelic stock as Trump signs on faster PTSD research - Seeking Alpha Mon, 20 Apr 2026 11
- Wall Street Analysts Think GH Research (GHRS) Could Surge 130.59%: Read This Before Placing a Bet - Yahoo Finance Mon, 10 Nov 2025 08
- How FDA’s Lifted Clinical Hold On GH001 At GH Research (GHRS) Has Changed Its Investment Story - Yahoo Finance Mon, 12 Jan 2026 08
- GH Research (NASDAQ: GHRS) CEO reports sizeable option grants and vesting - Stock Titan hu, 02 Apr 2026 07
- GH Research stock rises on upcoming trial update (GHRS:NASDAQ) - Seeking Alpha Fri, 02 Jan 2026 08
- GH Research (NASDAQ: GHRS) COO details multiple share option grants - Stock Titan hu, 02 Apr 2026 07
- RBC Capital Cite GH Research PLC’s (GHRS) Long-Term Sales Potential Following Psychedelics Symposium - Yahoo Finance Wed, 18 Feb 2026 08
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
60.68
+20.76%
|
50.25
+21.89%
|
41.22
+34.38%
|
30.68
|
| Research And Development |
|
38.77
+10.71%
|
35.02
+17.42%
|
29.82
+45.58%
|
20.48
|
| Selling General And Administration |
|
21.65
+44.32%
|
15.00
+34.90%
|
11.12
+10.59%
|
10.06
|
| General And Administrative Expense |
|
21.65
+44.32%
|
15.00
+34.90%
|
11.12
+10.59%
|
10.06
|
| Salaries And Wages |
|
8.70
+80.39%
|
4.82
+40.57%
|
3.43
+50.99%
|
2.27
|
| Other Gand A |
|
12.96
+27.24%
|
10.18
+32.37%
|
7.69
-1.19%
|
7.79
|
| Total Expenses |
|
60.68
+20.76%
|
50.25
+21.89%
|
41.22
+34.38%
|
30.68
|
| Operating Income |
|
-60.68
-20.76%
|
-50.25
-21.89%
|
-41.22
-34.38%
|
-30.68
|
| Total Operating Income As Reported |
|
-60.72
-20.68%
|
-50.31
-22.05%
|
-41.22
-34.92%
|
-30.55
|
| EBITDA |
|
-47.89
-24.07%
|
-38.60
-9.63%
|
-35.21
-57.12%
|
-22.41
|
| Normalized EBITDA |
|
-55.69
-25.63%
|
-44.33
-24.73%
|
-35.54
-18.88%
|
-29.89
|
| Reconciled Depreciation |
|
0.34
+6.35%
|
0.32
+0.00%
|
0.32
+570.21%
|
0.05
|
| EBIT |
|
-48.22
-23.93%
|
-38.91
-9.54%
|
-35.52
-58.19%
|
-22.46
|
| Total Unusual Items |
|
7.80
+36.18%
|
5.73
+1640.73%
|
0.33
-95.60%
|
7.48
|
| Total Unusual Items Excluding Goodwill |
|
7.80
+36.18%
|
5.73
+1640.73%
|
0.33
-95.60%
|
7.48
|
| Net Income |
|
-48.26
-23.86%
|
-38.96
-9.48%
|
-35.59
-58.47%
|
-22.46
|
| Pretax Income |
|
-48.26
-23.86%
|
-38.96
-9.48%
|
-35.59
-58.47%
|
-22.46
|
| Net Non Operating Interest Income Expense |
|
4.62
-16.89%
|
5.56
+4.77%
|
5.30
+621.77%
|
0.73
|
| Interest Expense Non Operating |
|
0.04
-27.08%
|
0.05
-23.81%
|
0.06
|
0.00
|
| Net Interest Income |
|
4.62
-16.89%
|
5.56
+4.77%
|
5.30
+621.77%
|
0.73
|
| Interest Expense |
|
0.04
-27.08%
|
0.05
-23.81%
|
0.06
|
0.00
|
| Interest Income Non Operating |
|
5.08
-19.01%
|
6.28
+4.10%
|
6.03
+602.56%
|
0.86
|
| Interest Income |
|
5.08
-19.01%
|
6.28
+4.10%
|
6.03
+602.56%
|
0.86
|
| Other Income Expense |
|
7.80
+36.18%
|
5.73
+1640.73%
|
0.33
-95.60%
|
7.48
|
| Gain On Sale Of Security |
|
7.80
+36.18%
|
5.73
+1640.73%
|
0.33
-95.60%
|
7.48
|
| Tax Provision |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-48.26
-23.86%
|
-38.96
-9.48%
|
-35.59
-58.47%
|
-22.46
|
| Net Income From Continuing Operation Net Minority Interest |
|
-48.26
-23.86%
|
-38.96
-9.48%
|
-35.59
-58.47%
|
-22.46
|
| Net Income From Continuing And Discontinued Operation |
|
-48.26
-23.86%
|
-38.96
-9.48%
|
-35.59
-58.47%
|
-22.46
|
| Net Income Continuous Operations |
|
-48.26
-23.86%
|
-38.96
-9.48%
|
-35.59
-58.47%
|
-22.46
|
| Normalized Income |
|
-56.06
-25.44%
|
-44.69
-24.42%
|
-35.92
-19.96%
|
-29.94
|
| Net Income Common Stockholders |
|
-48.26
-23.86%
|
-38.96
-9.48%
|
-35.59
-58.47%
|
-22.46
|
| Diluted EPS |
|
-0.79
-5.33%
|
-0.75
-10.29%
|
-0.68
-58.14%
|
-0.43
|
| Basic EPS |
|
-0.79
-5.33%
|
-0.75
-10.29%
|
-0.68
-58.14%
|
-0.43
|
| Basic Average Shares |
|
61.04
+17.51%
|
51.95
-0.74%
|
52.33
+0.60%
|
52.02
|
| Diluted Average Shares |
|
61.04
+17.51%
|
51.95
-0.74%
|
52.33
+0.60%
|
52.02
|
| Diluted NI Availto Com Stockholders |
|
-48.26
-23.86%
|
-38.96
-9.48%
|
-35.59
-58.47%
|
-22.46
|
| Depreciation Amortization Depletion Income Statement |
|
0.30
+2.72%
|
0.29
+5.00%
|
0.28
+1900.00%
|
0.01
|
| Depreciation And Amortization In Income Statement |
|
0.30
+2.72%
|
0.29
+5.00%
|
0.28
+1900.00%
|
0.01
|
| Depreciation Income Statement |
|
0.30
+2.72%
|
0.29
+5.00%
|
0.28
+1900.00%
|
0.01
|
| Provision For Doubtful Accounts |
|
-0.04
+36.36%
|
-0.07
-6500.00%
|
-0.00
-100.83%
|
0.12
|
| Total Other Finance Cost |
|
0.43
-36.02%
|
0.67
+1.36%
|
0.66
+436.59%
|
0.12
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
288.23
+53.09%
|
188.27
-16.80%
|
226.30
-11.03%
|
254.36
|
| Current Assets |
|
285.98
+85.43%
|
154.22
-6.01%
|
164.09
-2.64%
|
168.54
|
| Cash Cash Equivalents And Short Term Investments |
|
280.71
+87.99%
|
149.32
-7.57%
|
161.56
-2.65%
|
165.96
|
| Cash And Cash Equivalents |
|
246.25
+144.32%
|
100.79
+28.53%
|
78.42
-52.75%
|
165.96
|
| Cash Equivalents |
|
215.28
+198.11%
|
72.21
+95.01%
|
37.03
+3.72%
|
35.70
|
| Cash Financial |
|
30.97
+8.38%
|
28.58
-30.96%
|
41.39
-68.22%
|
130.25
|
| Other Short Term Investments |
|
34.46
-29.00%
|
48.53
-41.62%
|
83.14
|
0.00
|
| Receivables |
|
1.29
-25.23%
|
1.73
+483.16%
|
0.30
+230.00%
|
0.09
|
| Other Receivables |
|
1.16
-26.80%
|
1.58
+1229.41%
|
0.12
|
—
|
| Taxes Receivable |
|
0.14
-8.67%
|
0.15
-15.73%
|
0.18
+97.78%
|
0.09
|
| Prepaid Assets |
|
3.97
+25.37%
|
3.17
+41.98%
|
2.23
-8.86%
|
2.45
|
| Other Current Assets |
|
—
|
1.58
+1229.41%
|
0.12
+153.19%
|
0.05
|
| Total Non Current Assets |
|
2.25
-93.38%
|
34.05
-45.27%
|
62.21
-27.51%
|
85.82
|
| Net PPE |
|
0.62
-17.11%
|
0.75
-30.03%
|
1.07
+1002.06%
|
0.10
|
| Gross PPE |
|
1.68
+21.69%
|
1.38
-5.14%
|
1.46
+794.48%
|
0.16
|
| Accumulated Depreciation |
|
-1.06
-67.40%
|
-0.64
-63.24%
|
-0.39
-489.39%
|
-0.07
|
| Machinery Furniture Equipment |
|
—
|
0.26
+14.73%
|
0.22
+76.38%
|
0.13
|
| Other Properties |
|
1.68
+21.69%
|
1.38
+12.07%
|
1.23
+3327.78%
|
0.04
|
| Investments And Advances |
|
0.00
-100.00%
|
33.30
-45.54%
|
61.14
-28.68%
|
85.72
|
| Non Current Accounts Receivable |
|
1.63
|
—
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
8.53
-8.53%
|
9.32
+27.14%
|
7.33
+61.28%
|
4.55
|
| Current Liabilities |
|
8.38
-6.40%
|
8.95
+33.61%
|
6.70
+47.40%
|
4.55
|
| Payables And Accrued Expenses |
|
7.61
-4.83%
|
7.99
+29.88%
|
6.16
+38.28%
|
4.45
|
| Payables |
|
4.27
+3.44%
|
4.13
+7.73%
|
3.83
+83.69%
|
2.08
|
| Accounts Payable |
|
3.77
+0.86%
|
3.74
+7.19%
|
3.49
+86.83%
|
1.87
|
| Other Payable |
|
0.49
+28.57%
|
0.39
+13.24%
|
0.34
+56.68%
|
0.22
|
| Current Accrued Expenses |
|
3.34
-13.65%
|
3.87
+66.37%
|
2.33
-1.73%
|
2.37
|
| Current Debt And Capital Lease Obligation |
|
0.36
+43.14%
|
0.26
-25.66%
|
0.34
|
—
|
| Current Capital Lease Obligation |
|
0.36
+43.14%
|
0.26
-25.66%
|
0.34
|
0.00
|
| Other Current Liabilities |
|
0.41
-42.19%
|
0.70
+246.80%
|
0.20
+113.68%
|
0.10
|
| Total Non Current Liabilities Net Minority Interest |
|
0.15
-60.16%
|
0.37
-41.52%
|
0.63
|
0.00
|
| Long Term Debt And Capital Lease Obligation |
|
0.15
-60.16%
|
0.37
-41.52%
|
0.63
|
0.00
|
| Long Term Capital Lease Obligation |
|
0.15
-60.16%
|
0.37
-41.52%
|
0.63
|
0.00
|
| Stockholders Equity |
|
279.70
+56.30%
|
178.95
-18.28%
|
218.97
-12.35%
|
249.82
|
| Common Stock Equity |
|
279.70
+56.30%
|
178.95
-18.28%
|
218.97
-12.35%
|
249.82
|
| Capital Stock |
|
1.55
+19.22%
|
1.30
+0.00%
|
1.30
+0.00%
|
1.30
|
| Common Stock |
|
1.55
+19.22%
|
1.30
+0.00%
|
1.30
+0.00%
|
1.30
|
| Share Issued |
|
62.03
+19.22%
|
52.03
+0.00%
|
52.03
+0.01%
|
52.02
|
| Ordinary Shares Number |
|
62.03
+19.22%
|
52.03
+0.00%
|
52.03
+0.01%
|
52.02
|
| Additional Paid In Capital |
|
431.06
+47.90%
|
291.46
+0.00%
|
291.46
+0.01%
|
291.45
|
| Retained Earnings |
|
-154.43
-45.07%
|
-106.45
-56.68%
|
-67.94
-109.09%
|
-32.49
|
| Gains Losses Not Affecting Retained Earnings |
|
1.52
+120.58%
|
-7.37
-25.80%
|
-5.86
+43.91%
|
-10.44
|
| Other Equity Adjustments |
|
13.29
+155.91%
|
5.19
+11.67%
|
4.65
+79.23%
|
2.60
|
| Total Equity Gross Minority Interest |
|
279.70
+56.30%
|
178.95
-18.28%
|
218.97
-12.35%
|
249.82
|
| Total Capitalization |
|
279.70
+56.30%
|
178.95
-18.28%
|
218.97
-12.35%
|
249.82
|
| Working Capital |
|
277.60
+91.09%
|
145.27
-7.70%
|
157.39
-4.03%
|
164.00
|
| Invested Capital |
|
279.70
+56.30%
|
178.95
-18.28%
|
218.97
-12.35%
|
249.82
|
| Total Debt |
|
0.51
-17.95%
|
0.62
-35.93%
|
0.97
|
0.00
|
| Capital Lease Obligations |
|
0.51
-17.95%
|
0.62
-35.93%
|
0.97
|
0.00
|
| Net Tangible Assets |
|
279.70
+56.30%
|
178.95
-18.28%
|
218.97
-12.35%
|
249.82
|
| Tangible Book Value |
|
279.70
+56.30%
|
178.95
-18.28%
|
218.97
-12.35%
|
249.82
|
| Available For Sale Securities |
|
—
|
33.30
-45.54%
|
61.14
-28.68%
|
85.72
|
| Foreign Currency Translation Adjustments |
|
-11.78
+6.25%
|
-12.56
-19.55%
|
-10.51
+19.39%
|
-13.04
|
| Investmentin Financial Assets |
|
0.00
-100.00%
|
33.30
-45.54%
|
61.14
-28.68%
|
85.72
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-43.55
-3.00%
|
-42.28
-26.84%
|
-33.34
-27.24%
|
-26.20
|
| Cash Flow From Continuing Operating Activities |
|
-43.55
-3.00%
|
-42.28
-26.84%
|
-33.34
-27.24%
|
-26.20
|
| Net Income From Continuing Operations |
|
-48.26
-23.86%
|
-38.96
-9.48%
|
-35.59
-58.47%
|
-22.46
|
| Depreciation Amortization Depletion |
|
0.34
+6.35%
|
0.32
+0.00%
|
0.32
+570.21%
|
0.05
|
| Depreciation |
|
0.34
+6.35%
|
0.32
+0.00%
|
0.32
+570.21%
|
0.05
|
| Depreciation And Amortization |
|
0.34
+6.35%
|
0.32
+0.00%
|
0.32
+570.21%
|
0.05
|
| Other Non Cash Items |
|
-10.66
-16.48%
|
-9.16
-10.91%
|
-8.26
-691.47%
|
-1.04
|
| Stock Based Compensation |
|
8.50
+626.22%
|
1.17
-48.89%
|
2.29
+37.10%
|
1.67
|
| Provisionand Write Offof Assets |
|
-0.04
+36.36%
|
-0.07
-6500.00%
|
-0.00
-100.83%
|
0.12
|
| Operating Gains Losses |
|
-1.75
+17.66%
|
-2.13
-181.23%
|
2.62
+136.52%
|
-7.18
|
| Net Foreign Currency Exchange Gain Loss |
|
-1.75
+17.66%
|
-2.13
-181.23%
|
2.62
+136.52%
|
-7.18
|
| Change In Working Capital |
|
-3.09
-1745.74%
|
0.19
-88.57%
|
1.65
-23.81%
|
2.16
|
| Investing Cash Flow |
|
46.17
-29.11%
|
65.14
+220.40%
|
-54.10
+36.12%
|
-84.69
|
| Cash Flow From Continuing Investing Activities |
|
46.17
-29.11%
|
65.14
+220.40%
|
-54.10
+36.12%
|
-84.69
|
| Net PPE Purchase And Sale |
|
-0.12
-146.94%
|
-0.05
+51.00%
|
-0.10
-49.25%
|
-0.07
|
| Purchase Of PPE |
|
-0.12
-146.94%
|
-0.05
+51.00%
|
-0.10
-49.25%
|
-0.07
|
| Capital Expenditure |
|
-0.12
-146.94%
|
-0.05
+51.00%
|
-0.10
-49.25%
|
-0.07
|
| Net Investment Purchase And Sale |
|
46.29
-28.98%
|
65.18
+220.71%
|
-54.00
+36.19%
|
-84.62
|
| Purchase Of Investment |
|
0.00
|
0.00
+100.00%
|
-54.00
+36.19%
|
-84.62
|
| Sale Of Investment |
|
46.29
-28.98%
|
65.18
|
0.00
|
0.00
|
| Financing Cash Flow |
|
139.65
+46037.83%
|
-0.30
-49.02%
|
-0.20
|
0.00
|
| Cash Flow From Continuing Financing Activities |
|
139.65
+46037.83%
|
-0.30
-49.02%
|
-0.20
|
0.00
|
| Net Issuance Payments Of Debt |
|
-0.20
+35.20%
|
-0.30
-38.81%
|
-0.22
|
0.00
|
| Repayment Of Debt |
|
-0.20
+35.20%
|
-0.30
-38.81%
|
-0.22
|
0.00
|
| Long Term Debt Payments |
|
-0.20
+35.20%
|
-0.30
-38.81%
|
-0.22
|
0.00
|
| Net Long Term Debt Issuance |
|
-0.20
+35.20%
|
-0.30
-38.81%
|
-0.22
|
0.00
|
| Net Common Stock Issuance |
|
150.00
|
0.00
-100.00%
|
0.01
|
0.00
|
| Net Other Financing Charges |
|
-10.15
|
—
|
—
|
—
|
| Changes In Cash |
|
142.27
+531.03%
|
22.55
+125.73%
|
-87.64
+20.96%
|
-110.89
|
| Effect Of Exchange Rate Changes |
|
3.19
+1922.29%
|
-0.17
-266.67%
|
0.10
+59.09%
|
0.07
|
| Beginning Cash Position |
|
100.79
+28.53%
|
78.42
-52.75%
|
165.96
-40.04%
|
276.78
|
| End Cash Position |
|
246.25
+144.32%
|
100.79
+28.53%
|
78.42
-52.75%
|
165.96
|
| Free Cash Flow |
|
-43.67
-3.16%
|
-42.33
-26.61%
|
-33.44
-27.30%
|
-26.27
|
| Common Stock Issuance |
|
150.00
|
0.00
-100.00%
|
0.01
|
0.00
|
| Interest Paid CFO |
|
-0.64
+11.62%
|
-0.72
-11.57%
|
-0.65
-2845.45%
|
-0.02
|
| Interest Received CFO |
|
12.06
+70.44%
|
7.08
+65.21%
|
4.28
+756.60%
|
0.50
|
| Issuance Of Capital Stock |
|
150.00
|
0.00
-100.00%
|
0.01
|
0.00
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|